Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure

Next Previous
X
Search
Trial Profile

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ampreloxetine (Primary)
  • Indications Orthostatic hypotension
  • Focus Registrational; Therapeutic Use
  • Acronyms REDWOOD
  • Sponsors Theravance Biopharma

    • Most Recent Events

    • 12 Nov 2024 According to a Theravance Biopharma media release, the corporate presentation under the Investors section, Events and Presentations, shows that CYPRESS is designed to reproduce study 0170 MSA patient results. A positive outcome of CYPRESS trial, supported by Study 0170 data, are expected to be sufficient for regulatory filing.
    • 31 Jan 2024 This trial has been Discontinued in Portugal, According to European Clinical Trials Database.
    • 16 Nov 2023 Results published in the Theravance Biopharma Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top